<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859651</url>
  </required_header>
  <id_info>
    <org_study_id>AAAD3638</org_study_id>
    <nct_id>NCT00859651</nct_id>
  </id_info>
  <brief_title>Vitamin D in Postmenopausal Women at High Risk for Breast Cancer</brief_title>
  <official_title>Effects of High-Dose Vitamin D on Circulating Vitamin D Levels and Breast Density in Postmenopausal Women at High Risk for Breast Cancer Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avon Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study which will enroll 20 postmenopausal women who are at high risk for
      breast cancer development. The goal is to determine whether a one-year intervention of
      high-dose vitamin D at 2 different doses (20,000 IU weekly or 30,000 IU weekly) will increase
      circulating blood levels of vitamin D and to obtain preliminary data on the biologic effects
      of vitamin D for breast cancer prevention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive oral vitamin D3, cholecalciferol 20,000 IU or 30,000 IU weekly.
      Before beginning the intervention, the participants will have a general physical exam
      including a clinical breast exam and anthropometric measures, a morning blood draw (for
      analysis of 25(OH)D, 1,25(OH)D, parathyroid hormone (PTH), insulin-like growth factor
      (IGF)-I, insulin-like growth factor-binding protein 3 (IGFBP-3), estradiol, estrone,
      testosterone, and sex hormone-binding globulin (SHBG) at baseline, 6 months, and 12 months)
      and a bilateral mammogram (at baseline and 12 months). Participants will also complete a
      baseline questionnaire, collecting data on demographic information and breast cancer risk
      factors. In addition, we will be collecting data on vitamin D sources from diet and sunlight
      exposure using a validated questionnaire administered at baseline and 12 months.

      For follow-up visits, the participant will be seen at the study site at months 3, 6, 9, and
      12. During these visits, drug will be dispensed, adherence ascertained, and adverse events
      will also be assessed. In addition, blood (serum calcium, albumin, creatinine) and urine
      (urine calcium, creatinine) will be collected to monitor for toxicity. A 24-hour urine
      collection will be conducted at baseline and 12 months to assess for hypercalciuria. After
      the 1 year intervention, all participants will have a complete physical exam including
      clinical breast exam, a bilateral mammogram, blood draw, and complete a follow-up
      questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum 25(OH)D</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>25(OH)D level at the end of one year intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Density</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>Assessed by mammography and breast MRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>20,000 IU weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.
Cholecalciferol 20,000 IU (2 active capsules + 1 matching placebo capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30,000 IU weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.
Cholecalciferol 30,000 IU (3 active capsules)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.
Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each.</description>
    <arm_group_label>20,000 IU weekly</arm_group_label>
    <arm_group_label>30,000 IU weekly</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Matching placebo capsules</description>
    <arm_group_label>20,000 IU weekly</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elevated risk of breast cancer defined as having at least one of the following: (1)
             Predicted 5-year modified Gail model risk of 1.67% or greater, (2) Lobular carcinoma
             in situ, (3) Known BRCA1 or BRCA2 deleterious mutation carrier, (4) Prior history of
             ductal carcinoma in situ, if no current tamoxifen use or prior radiation to the
             contralateral breast.

          -  Age 21 years or older.

          -  Postmenopausal defined as &gt; 6 months since the last menstrual period, prior bilateral
             oophorectomy, or serum follicle-stimulating hormone (FSH)/luteinizing hormone (LH)
             values consistent with institutional normal values for the postmenopausal state.

          -  Baseline mammographic density â‰¥25% as assessed qualitatively by the mammographer
             (25-50% = &quot;scattered fibroglandular densities&quot;; &gt;50-75% = &quot;heterogeneously dense
             breasts&quot;; &gt;75% = &quot;extremely dense breasts&quot;).

          -  Baseline serum 25-hydroxyvitamin D &lt;32 ng/ml.

          -  Normal breast exam and mammogram (Breast Imaging Reporting and Data System (BIRADS)
             score of 1 or 2) or abnormal breast imaging with a benign breast biopsy without
             evidence of cancer. Normal baseline breast magnetic resonance imaging (MRI) (BIRADS
             score of 1, 2, or 3).

          -  Prior tamoxifen or raloxifene use is allowed provided treatment is discontinued at
             least 28 days prior to enrollment.

          -  At least one breast available for imaging. No bilateral breast implants.

          -  Willingness to not take vitamin D supplements during the one year intervention, but up
             to 1000mg of calcium supplementation is allowed.

          -  Normal serum calcium.

          -  Adequate renal and hepatic function: serum creatinine, bilirubin, aspartate
             aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase &lt; 2.0
             x the institutional upper limit of normal (IULN).

          -  Performance status of 0 or 1.

        Exclusion Criteria:

          -  Other prior malignancy. The following is allowed: adequately treated basal cell or
             squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II
             cancer from which the participant is currently in complete remission, or any other
             cancer (including breast cancer) for which the participant has been disease-free for 5
             years.

          -  History of kidney stones.

          -  Hypersensitivity reactions to vitamin D.

          -  On estrogen replacement therapy.

          -  Significant medical or psychiatric condition that would preclude study completion.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine D Crew, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <results_first_submitted>May 5, 2016</results_first_submitted>
  <results_first_submitted_qc>August 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2017</results_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Katherine D. Crew</investigator_full_name>
    <investigator_title>Associate Professor of Medicine and Associate Professor of Epidemiology</investigator_title>
  </responsible_party>
  <keyword>breast cancer chemoprevention</keyword>
  <keyword>vitamin D</keyword>
  <keyword>breast density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Data for this study (NCT00859651; n=20 postmenopausal; 8 received 20,000 IU/week and 12 received 30,000 IU/week) is combined with the data for another study (NCT00976339; n=20 premenopausal; 10 received 20,000 IU/week and 10 received 30,000 IU/week). Resulting in a combination of 18 receiving 20,000 IU/week and 22 receiving 30,000 IU/week.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cholecalciferol 20,000 IU Group</title>
          <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.</description>
        </group>
        <group group_id="P2">
          <title>Cholecalciferol 30,000 IU Group</title>
          <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data for this study (NCT00859651; n=20) is combined with the data for another study (NCT00976339; n=20).</population>
      <group_list>
        <group group_id="B1">
          <title>Cholecalciferol 20,000 IU Group</title>
          <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.</description>
        </group>
        <group group_id="B2">
          <title>Cholecalciferol 30,000 IU Group</title>
          <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" lower_limit="45" upper_limit="73"/>
                    <measurement group_id="B2" value="50.5" lower_limit="37" upper_limit="69"/>
                    <measurement group_id="B3" value="50" lower_limit="37" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum 25(OH)D</title>
        <description>25(OH)D level at the end of one year intervention</description>
        <time_frame>Baseline to 1 year</time_frame>
        <population>Data for this study (NCT00859651; n=20) is combined with the data for another study (NCT00976339; n=20).</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol 20,000 IU Group</title>
            <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol 30,000 IU Group</title>
            <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum 25(OH)D</title>
          <description>25(OH)D level at the end of one year intervention</description>
          <population>Data for this study (NCT00859651; n=20) is combined with the data for another study (NCT00976339; n=20).</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="5"/>
                    <measurement group_id="O2" value="33" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Density</title>
        <description>Assessed by mammography and breast MRI.</description>
        <time_frame>Baseline to 1 year</time_frame>
        <population>Data for this study (NCT00859651; n=20) is combined with the data for another study (NCT00976339; n=20).</population>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol 20,000 IU Group</title>
            <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol 30,000 IU Group</title>
            <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Density</title>
          <description>Assessed by mammography and breast MRI.</description>
          <population>Data for this study (NCT00859651; n=20) is combined with the data for another study (NCT00976339; n=20).</population>
          <units>percentage of breast density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1"/>
                    <measurement group_id="O2" value="1" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>For the Outcome Measure data analysis, the investigator combined the data for this study (NCT00859651; n=20) with the data for another study (NCT00976339; n=20), since both studies are under the same investigational new drug (IND). Therefore, the total number of participants analyzed is 40.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cholecalciferol 20,000 IU</title>
          <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.</description>
        </group>
        <group group_id="E2">
          <title>Cholecalciferol 30,000 IU</title>
          <description>Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalciuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The investigator combined the data for this study (NCT00859651; n=20) with the data for another study (NCT00976339; n=20). Therefore, the total number of participants analyzed is 40 for Outcome Measures and Adverse Events sections.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Katherine Crew, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-1732</phone>
      <email>kd59@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

